Open questions for Alzheimer’s disease immunotherapy

Pyroglutamate-3 Amyloid-β Deposition in the Brains of Humans, Non-Human Primates, Canines, and Alzheimer Disease–Like Transgenic Mouse Models

(2013) Jeffrey L. Frost et al.   AMERICAN JOURNAL OF PATHOLOGY

Brain-wide pathway for waste clearance captured by contrast-enhanced MRI

(2013) Jeffrey J. Iliff et al.   JOURNAL OF CLINICAL INVESTIGATION

Evaluating glymphatic pathway function utilizing clinically relevant intrathecal infusion of CSF tracer

(2013) Lijun Yang et al.   Journal of Translational Medicine

Physiology of Blood–Brain Interfaces in Relation to Brain Disposition of Small Compounds and Macromolecules

(2013) N. Strazielle et al.   MOLECULAR PHARMACEUTICS

Transgenic expression of β1 antibody in brain neurons impairs age-dependent amyloid deposition in APP23 mice

(2013) Paolo Paganetti et al.   NEUROBIOLOGY OF AGING

Anti-Tau Antibodies that Block Tau Aggregate Seeding In Vitro Markedly Decrease Pathology and Improve Cognition In Vivo

(2013) Kiran Yanamandra et al.   NEURON

Developing Therapeutic Antibodies for Neurodegenerative Disease

(2013) Y. Joy Yu et al.   Neurotherapeutics

Treating Alzheimer’s disease with monoclonal antibodies: current status and outlook for the future

(2013) Niels D Prins et al.   Alzheimers Research & Therapy

Immunoglobulin G Fc receptor deficiency prevents Alzheimer-like pathology and cognitive impairment in mice

(2012) P. Fernandez-Vizarra et al.   BRAIN

An Effector-Reduced Anti- -Amyloid (A ) Antibody with Unique A  Binding Properties Promotes Neuroprotection and Glial Engulfment of A 

(2012) O. Adolfsson et al.   JOURNAL OF NEUROSCIENCE

Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis

(2012) Reisa Sperling et al.   LANCET NEUROLOGY

Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study

(2012) Bengt Winblad et al.   LANCET NEUROLOGY

Investigation of the Role of FcγR and FcRn in mAb Distribution to the Brain

(2012) Lubna Abuqayyas et al.   MOLECULAR PHARMACEUTICS

A Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice

(2012) Ronald B. DeMattos et al.   NEURON

Propagation of Tau Pathology in a Model of Early Alzheimer's Disease

(2012) Alix de Calignon et al.   NEURON

Trans-Synaptic Spread of Tau Pathology In Vivo

(2012) Li Liu et al.   PLoS One

A Paravascular Pathway Facilitates CSF Flow Through the Brain Parenchyma and the Clearance of Interstitial Solutes, Including Amyloid  

(2012) J. J. Iliff et al.   Science Translational Medicine

Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab

(2011) Susanne Ostrowitzki   ARCHIVES OF NEUROLOGY

Intracellular antibody-mediated immunity and the role of TRIM21

(2011) William A. McEwan et al.   BIOESSAYS

NMDA Receptor Antibody Encephalitis

(2011) Sarosh R. Irani et al.   Current Neurology and Neuroscience Reports

Movement disorders in paraneoplastic and autoimmune disease

(2011) Jessica Panzer et al.   CURRENT OPINION IN NEUROLOGY

Pyroglutamate Amyloid-β (Aβ): A Hatchet Man in Alzheimer Disease

(2011) Sadim Jawhar et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Immunotherapy for Tauopathies

(2011) Jiaping Gu et al.   JOURNAL OF MOLECULAR NEUROSCIENCE

Autoreactive-Aβ antibodies promote APP β-secretase processing

(2011) Juan Deng et al.   JOURNAL OF NEUROCHEMISTRY

In Vivo Microdialysis Reveals Age-Dependent Decrease of Brain Interstitial Fluid Tau Levels in P301S Human Tau Transgenic Mice

(2011) K. Yamada et al.   JOURNAL OF NEUROSCIENCE

Nitration of Tyrosine 10 Critically Enhances Amyloid β Aggregation and Plaque Formation

(2011) Markus P. Kummer et al.   NEURON

Anti-Aβ Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift

(2011) Todd E. Golde et al.   NEURON

A Therapeutic Antibody Targeting BACE1 Inhibits Amyloid-  Production in Vivo

(2011) J. K. Atwal et al.   Science Translational Medicine

Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target

(2011) Y. J. Yu et al.   Science Translational Medicine

Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Aβ42 immunisation in Alzheimer’s disease

(2010) Delphine Boche et al.   ACTA NEUROPATHOLOGICA

11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

(2010) Juha O Rinne et al.   LANCET NEUROLOGY

Quantitative and Mechanistic Studies of Aβ Immunotherapy

(2009) Todd Golde et al.   CNS & Neurological Disorders-Drug Targets

Intracerebroventricular amyloid-  antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice

(2009) D. R. Thakker et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease

(2009) Roy O Weller et al.   Alzheimers Research & Therapy

Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

(2008) Clive Holmes et al.   LANCET

Antibody Capture of Soluble Aβ Does Not Reduce Cortical Aβ Amyloidosis in the PDAPP Mouse

(2008) Peter Seubert et al.   Neurodegenerative Diseases